| Schedule of Segment Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
($ in thousands) |
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Three Months Ended September 30, 2023 |
|
Sales1 |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
34,539 |
|
$ |
213 |
|
$ |
34,752 |
Cost of goods - product revenue |
|
|
(6,429) |
|
|
— |
|
|
(6,429) |
Research and development |
|
|
(2,229) |
|
|
(18,119) |
|
|
(20,348) |
Selling, general and administrative |
|
|
(8,636) |
|
|
(13,097) |
|
|
(21,733) |
Other expense |
|
|
(361) |
|
|
3,536 |
|
|
3,175 |
Income tax expense |
|
|
(95) |
|
|
(46) |
|
|
(141) |
Segment income (loss) |
|
$ |
16,789 |
|
|
(27,513) |
|
$ |
(10,724) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Nine Months Ended September 30, 2023 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
63,924 |
|
$ |
643 |
|
$ |
64,567 |
Cost of goods - product revenue |
|
|
(20,645) |
|
|
— |
|
|
(20,645) |
Research and development |
|
|
(6,036) |
|
|
(85,959) |
|
|
(91,995) |
Selling, general and administrative |
|
|
(34,069) |
|
|
(37,443) |
|
|
(71,512) |
Asset impairment |
|
|
(3,143) |
|
|
— |
|
|
(3,143) |
Other income |
|
|
(1,646) |
|
|
(654) |
|
|
(2,300) |
Income tax expense |
|
|
(95) |
|
|
(47) |
|
|
(142) |
Segment loss |
|
$ |
(1,710) |
|
$ |
(123,460) |
|
$ |
(125,170) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
($ in thousands) |
|
Products |
|
Product |
|
|
|
Three Months Ended September 30, 2022 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
16,116 |
|
$ |
412 |
|
$ |
16,528 |
Cost of goods - product revenue |
|
|
(7,221) |
|
|
— |
|
|
(7,221) |
Research and development |
|
|
(2,812) |
|
|
(27,090) |
|
|
(29,902) |
Selling, general and administrative |
|
|
(15,574) |
|
|
(14,565) |
|
|
(30,139) |
Other expense |
|
|
(577) |
|
|
(1,749) |
|
|
(2,326) |
Segment loss |
|
$ |
(10,068) |
|
$ |
(42,992) |
|
$ |
(53,060) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Nine Months Ended September 30, 2022 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
57,703 |
|
$ |
1,636 |
|
$ |
59,339 |
Cost of goods - product revenue |
|
|
(23,057) |
|
|
— |
|
|
(23,057) |
Research and development |
|
|
(6,687) |
|
|
(93,068) |
|
|
(99,755) |
Selling, general and administrative |
|
|
(45,517) |
|
|
(39,940) |
|
|
(85,457) |
Other expense |
|
|
(1,413) |
|
|
(6,125) |
|
|
(7,538) |
Segment loss |
|
$ |
(18,971) |
|
$ |
(137,497) |
|
$ |
(156,468) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
($ in thousands) |
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
September 30, 2023 |
|
Sales |
|
Development |
|
Total Assets |
Intangible assets, net |
|
$ |
21,102 |
|
$ |
— |
|
$ |
21,102 |
Tangible assets |
|
|
44,816 |
|
|
84,631 |
|
|
129,447 |
Total segment assets |
|
$ |
65,918 |
|
$ |
84,631 |
|
$ |
150,549 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
($ in thousands) |
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
December 31, 2022 |
|
Sales |
|
Development |
|
Total Assets |
Intangible assets, net |
|
$ |
27,197 |
|
$ |
— |
|
$ |
27,197 |
Tangible assets |
|
|
77,963 |
|
|
189,141 |
|
|
267,104 |
Total segment assets |
|
$ |
105,160 |
|
$ |
189,141 |
|
$ |
294,301 |
|